EOLS vs. ADMS, HCM, PBH, CORT, MRUS, BHVN, FOLD, XENE, ARWR, and PTCT
Should you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Adamas Pharmaceuticals (ADMS), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), Merus (MRUS), Biohaven (BHVN), Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), and PTC Therapeutics (PTCT). These companies are all part of the "medical" sector.
Evolus (NASDAQ:EOLS) and Adamas Pharmaceuticals (NASDAQ:ADMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.
In the previous week, Evolus had 3 more articles in the media than Adamas Pharmaceuticals. MarketBeat recorded 3 mentions for Evolus and 0 mentions for Adamas Pharmaceuticals. Evolus' average media sentiment score of 1.58 beat Adamas Pharmaceuticals' score of 0.00 indicating that Evolus is being referred to more favorably in the media.
Evolus has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Adamas Pharmaceuticals has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500.
90.7% of Evolus shares are held by institutional investors. Comparatively, 70.0% of Adamas Pharmaceuticals shares are held by institutional investors. 6.1% of Evolus shares are held by company insiders. Comparatively, 18.9% of Adamas Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Adamas Pharmaceuticals received 60 more outperform votes than Evolus when rated by MarketBeat users. However, 72.00% of users gave Evolus an outperform vote while only 59.12% of users gave Adamas Pharmaceuticals an outperform vote.
Adamas Pharmaceuticals has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Adamas Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Evolus has a net margin of -27.31% compared to Adamas Pharmaceuticals' net margin of -71.11%.
Evolus presently has a consensus price target of $21.25, indicating a potential upside of 64.35%. Given Evolus' higher probable upside, research analysts plainly believe Evolus is more favorable than Adamas Pharmaceuticals.
Summary
Evolus beats Adamas Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Evolus News Delivered to You Automatically
Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
